Biologic Licence Application

Biologic Licence Application designates the regulatory submission to the United States FDA requesting approval to market a biological product, replacing the former Product Licence Application and Establishment Licence Application with a single integrated submission demonstrating product safety, purity, and potency manufactured at facilities meeting applicable standards.

The pharmaceutical industry prepares Biologic Licence Applications as comprehensive dossiers incorporating quality, nonclinical, and clinical data packages. The application structure follows ICH Common Technical Document format with modules addressing administrative information, summaries, quality documentation, nonclinical study reports, and clinical study reports. Chemistry, manufacturing, and controls sections describe biological product manufacturing with extensive characterisation data. Clinical efficacy and safety data from pivotal trials support benefit-risk assessment. Post-marketing commitments address outstanding questions. As biologics pipelines expand and regulatory expectations for characterisation increase, Biologic Licence Application preparation requires sophisticated analytical programmes and integrated regulatory strategies developed throughout the development programme.